Drug Enforcement Administration (DEA), Justice.
Notice of proposed revised 2003 aggregate production quotas.
This notice proposes revised 2003 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA).
Comments or objections must be received on or before August 27, 2003.
Send comments or objections to the Acting Administrator, Drug Enforcement Administration, Washington, DC 20537, Attn.: DEA Federal Register Representative (CCR).Start Further Info
FOR FURTHER INFORMATION CONTACT:
Frank L. Sapienza, Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307-7183.End Further Info End Preamble Start Supplemental Information
Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by § 0.100 of Title 28 of the Code of Federal Regulations.
On December 19, 2002, DEA published a notice of established initial 2003 aggregate production quotas for certain controlled substances in Schedules I and II (67 FR 77809). This notice stipulated that the DEA would adjust the quotas in early 2003 as provided for in part 1303 of Title 21 of the Code of Federal Regulations.
The proposed revised 2003 aggregate production quotas represent those quantities of controlled substances in Schedules I and II that may be produced in the United States in 2003 to provide adequate supplies of each substance for: The estimated medical, scientific, research and industrial needs of the United States; lawful export requirements; and the establishment and maintenance of reserve stocks. These quotas do not include imports of controlled substances for use in industrial processes.
The proposed revisions are based on a review of 2002 year-end inventories, 2002 disposition data submitted by quota applicants, estimates of the medical needs of the United States, product development, and other information available to the DEA.
Therefore, under the authority vested in the Attorney General by section 306 of the CSA of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by § 0.100 of Title 28 of the Code of Federal Regulations, the Acting Administrator hereby proposes the following revised 2003 aggregate production quotas for the following controlled substances, expressed in grams of anhydrous acid or base:
|Basic class||Previously established initial 2003 quotas||Proposed revised 2003 quotas|
|Start Printed Page 46665|
|Lysergic acid diethylamide (LSD)||61||61|
|Codeine (for sale)||43,494,000||43,494,000|
|Codeine (for conversion)||43,559,000||43,559,000|
|Hydrocodone (for sale)||29,243,000||29,543,000|
|Hydrocodone (for conversion)||3,800,000||3,800,000|
|Start Printed Page 46666|
|Methadone (for sale)||14,057,000||14,057,000|
|Methamphetamine [704,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 1,420,000 grams for methamphetamine mostly for conversion to a Schedule III product; and 1,000 grams for methamphetamine (for sale)]||2,325,000||2,125,000|
|Morphine (for sale)||18,218,000||20,252,000|
|Morphine (for conversion)||110,774,000||110,774,000|
|Noroxymorphone (for sale)||40,000||80,000|
|Noroxymorphone (for conversion)||4,400,000||4,400,000|
|Oxycodone (for sale)||34,482,000||39,090,000|
|Oxycodone (for conversion)||700,000||700,000|
The Acting Administrator further proposes that aggregate production quotas for all other Schedules I and II controlled substances included in §§ 1308.11 and 1308.12 of Title 21 of the Code of Federal Regulations remain at zero.
All interested persons are invited to submit their comments and objections in writing regarding this proposal. A person may object to or comment on the proposal relating to any of the above-mentioned substances without filing comments or objections regarding the others. If a person believes that one or more of these issues warrant a hearing, the individual should so state and summarize the reasons for this belief.
In the event that comments or objections to this proposal raise one or more issues which the Acting Administrator finds warrant a hearing, the Acting Administrator shall order a public hearing by notice in the Federal Register, summarizing the issues to be heard and setting the time for the hearing as per 21 CFR 1303.13(c) and 1303.32.
The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866.
This action does not preempt or modify any provision of state law; nor does it impose enforcement responsibilities on any state; nor does it diminish the power of any state to enforce its own laws. Accordingly, this action does not have federalism implications warranting the application of Executive Order 13132.
The Acting Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et seq. The establishment of aggregate production quotas for Schedules I and II controlled substances is mandated by law and by international treaty obligations. The quotas are necessary to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and the establishment and maintenance of reserve stocks. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Acting Administrator has determined that this action does not require a regulatory flexibility analysis.
This action meets the applicable standards set forth in sections 3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform.
This action will not result in the expenditure by State, local, and Tribal governments, in the aggregate, or by the private sector, of $100,000,000 or more in any one year, and will not significantly or uniquely affect small governments. Therefore, no actions were deemed necessary under the provisions of the Unfunded Mandates Reform Act of 1995.
This action is not a major rule as defined by section 804 of the Small Business Regulatory Enforcement Fairness Act of 1996. This action will not result in an annual effect on the economy of $100,000,000 or more; a major increase in costs or prices; or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of United States-based companies to compete with foreign-based companies in domestic and export markets.
The DEA makes every effort to write clearly. If you have suggestions as to how to improve the clarity of this regulation, call or write Frank L. Sapienza, Chief, Drug & Chemical Evaluation Section, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307-7183.Start Signature
Dated: July 31, 2003.
William B. Simpkins,
[FR Doc. 03-19954 Filed 8-5-03; 8:45 am]
BILLING CODE 4410-09-P